High frequency of voriconazole-related phototoxicity in cystic fibrosis patients
| Autor: | Christophe Marguet, Stéphane Dominique, L. Favennec, S. Pramil, Laure Couderc, B. Masseline, C. Leguillon, S. Rondeau |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Pulmonary and Respiratory Medicine
Adult Male medicine.medical_specialty Antifungal Agents Adolescent Cystic Fibrosis Itraconazole Aspergillosis Gastroenterology Cystic fibrosis Severity of Illness Index Aspergillus fumigatus Young Adult Internal medicine medicine Humans Adverse effect Child Voriconazole biology business.industry Triazoles medicine.disease biology.organism_classification Cystic fibrosis transmembrane conductance regulator Pyrimidines Child Preschool Immunology biology.protein Female Allergic bronchopulmonary aspergillosis business medicine.drug Dermatitis Phototoxic |
| Zdroj: | The European respiratory journal. 39(3) |
| ISSN: | 1399-3003 |
| Popis: | To the Editors: Aspergillus fumigatus infection is common in cystic fibrosis (CF) patients and estimates of the rate of allergic bronchopulmonary aspergillosis range from 1–15%. Voriconazole, a new triazole antifungal, has been recognised as efficient and safe in the treatment of invasive aspergillosis [1–2]. Since it is available orally, voriconazole became the first alternative to itraconazole. We began giving voriconazole to CF patients in 2003, and we encountered an unexpectedly high frequency of moderate-to-severe skin reactions, which limited the administration of the drug. We therefore reviewed all the medical files of children (aged |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|